Log in Book a Demo

US Pharma & Biotech Neuroscience - PPC Market Share Analysis April 2025

Leveraging Adthena’s Whole Market View, this analysis explores recent trends in Google Ads for the US Neuroscience category from the last month. Our Data Analyst, Ask Arlo provides commentary on key findings.

Market Exposure

Share of Clicks for top 10 US Pharma & Biotech Neuroscience brands

Here are the Top 10 competitors in the industry by Share of Clicks for the last month.

See more data
Share of Clicks - Last month
Domain Share of clicks
vraylar.com 29.98
nurtec.com 15.45
caplyta.com 10.54
vyepti.com 4.18
vraylarhcp.com 3.73
ubrelvy.com 3.4
fanapt.com 2.93
nurtec-hcp.com 2.57
cobenfyhcp.com 2.14
rexulti.com 1.73
others 23.35

Copyright © Adthena. All rights reserved.

In the PPC landscape, vraylar.com leads with 29.98% click share, followed by others at 23.35%. Nurtec.com captures 15.45%, while caplyta.com holds 10.54%.

Market Exposure

Share of Spend for the top 10 US Pharma & Biotech Neuroscience brands

Curious about your market position? Here you can see the Top 10 competitors in the industry by Share of Spend for the last month. 

See more data
Share of Spend - Last Month
Date vraylar.com caplyta.com nurtec.com vraylarhcp.com ubrelvy.com vyepti.com fanapt.com wakix.com nurtec-hcp.com mavenclad.com
2025/04/01 0% 0% 27.03% 38.6% 0% 0.12% 0% 6.36% 4.37% 0%
2025/04/02 0% 0% 24.33% 31.37% 0% 0.02% 4.8% 6.29% 3.1% 0%
2025/04/03 0% 0% 18.18% 15.84% 0% 0.01% 8.81% 4.8% 12.69% 0%
2025/04/04 0% 0% 18.11% 8.75% 2.05% 1.57% 9.15% 5.77% 2.51% 2.22%
2025/04/05 35.84% 11.4% 8.87% 8.34% 0.83% 0.35% 2.92% 4.81% 1.08% 1.09%
2025/04/06 20.2% 15.93% 7.03% 0% 2.4% 0.3% 6.15% 3.42% 0.8% 0.92%
2025/04/07 40.39% 3.14% 7.34% 0.05% 8.24% 6.31% 4.7% 0.6% 0.81% 1.83%
2025/04/08 47.99% 0% 7.99% 3.41% 1.19% 0.42% 1.72% 3.07% 1.21% 2.55%
2025/04/09 16.1% 5.04% 12.75% 0% 12.77% 11.06% 1.22% 3.28% 4.78% 2.91%
2025/04/10 10.45% 3.24% 8.74% 0% 4.34% 10.21% 2.46% 2.28% 5.73% 2.95%
2025/04/11 21.37% 9.98% 12.3% 3.72% 13.7% 11.79% 0.92% 2.15% 5.68% 1.04%
2025/04/12 17.88% 5.47% 12.64% 5.1% 1.44% 4.38% 4.55% 3.23% 1.61% 6.05%
2025/04/13 28.63% 0% 14.82% 4.96% 6.56% 9.41% 4.87% 2.27% 4.33% 0.04%
2025/04/14 31.54% 12.97% 8.1% 7.34% 0.27% 2.63% 2.63% 0.64% 0.86% 3.58%
2025/04/15 54.33% 8.66% 7.98% 5.7% 0.53% 2.11% 1.37% 0.83% 1.34% 0.05%
2025/04/16 0% 0.19% 17.91% 21.98% 1.76% 4.87% 3.75% 4.54% 2.3% 4.36%
2025/04/17 29.78% 10.39% 4.1% 3.14% 5.33% 7.82% 2.65% 2.2% 2.63% 3.65%
2025/04/18 31.79% 10.22% 5.48% 0.07% 8.7% 4.5% 1.49% 1.19% 3.2% 3.25%
2025/04/19 41.49% 15.83% 4.74% 2.89% 3.76% 5.56% 2.33% 0.78% 2.3% 1.33%
2025/04/20 19.35% 16.5% 7.68% 0.05% 4.24% 3.65% 2.88% 2.3% 2.43% 3.89%
2025/04/21 47.91% 11.52% 5.15% 2.14% 2.92% 2.09% 1.78% 0.36% 1.53% 1.7%
2025/04/22 39.98% 9.58% 8.25% 0% 6.08% 2.51% 1.06% 2.47% 4.9% 1.02%
2025/04/23 0% 23.58% 6.1% 0% 12.65% 9.74% 0.01% 1.38% 3.69% 6.99%
2025/04/24 40.03% 12.73% 14.22% 0.11% 1.72% 7.11% 0.15% 0.66% 4.83% 1.28%
2025/04/25 30.5% 0.95% 13.75% 0.32% 4.92% 1.39% 4.31% 0.12% 1.07% 5.81%
2025/04/26 49.94% 19.74% 6.29% 0% 5.34% 2.01% 0% 0.64% 0.41% 0%
2025/04/27 0% 56.68% 11.2% 0% 0.84% 1.01% 2.57% 3.39% 0.48% 0%
2025/04/28 20.8% 25.76% 7.99% 14.35% 1.69% 1.36% 0% 0.02% 0.65% 3.8%
2025/04/29 57.55% 10.89% 5.64% 8.15% 1.02% 0.48% 0% 0.33% 0.35% 1.06%
2025/04/30 38.47% 12.18% 8.92% 4.56% 4.15% 2.65% 1.42% 1.26% 0.24% 0%

Copyright © Adthena. All rights reserved.

In April 2025, Vraylar.com led with fluctuating spend, peaking at 57.55. Caplyta.com saw a significant rise on April 27, reaching 56.68. Nurtec.com maintained moderate activity, while Vraylarhcp.com and Ubrelvy.com had sporadic peaks. The month concluded with Vraylar.com dominating.

Market Exposure

Competitor Count for US Pharma & Biotech Neuroscience

Ever wondered how many competitors you’re up against in your industry? Well look no further, here we can see the number of advertisers bidding over the last month. 

See more data
Competitor Count - Last month
Date Competitor Count
2025/04/01 52
2025/04/02 54
2025/04/03 59
2025/04/04 68
2025/04/05 73
2025/04/06 78
2025/04/07 71
2025/04/08 75
2025/04/09 78
2025/04/10 73
2025/04/11 78
2025/04/12 76
2025/04/13 77
2025/04/14 78
2025/04/15 75
2025/04/16 65
2025/04/17 70
2025/04/18 79
2025/04/19 75
2025/04/20 77
2025/04/21 73
2025/04/22 72
2025/04/23 73
2025/04/24 63
2025/04/25 53
2025/04/26 48
2025/04/27 46
2025/04/28 52
2025/04/29 52
2025/04/30 48

Copyright © Adthena. All rights reserved.

April began with 52 advertisers, peaking at 79 mid-month. A decline followed, ending at 48.

Campaign Efficiency

Market Loss & Market Gains for US Pharma & Biotech Neuroscience

Here we’re looking at the Top 10 biggest industry movers by market share gains and losses for the last 30 days.

See more data
Market Loss & Market Gains - Last month
Name Market Trend
caplyta.com 9.5%
vraylar.com 8.72%
excedrin.com 1.53%
ubrelvy.com 1.07%
kesimptahcp.com 0.61%
briumvi.com -1.35%
vraylarhcp.com -2.2%
fanapt.com -2.23%
rexulti.com -3.82%
nurtec.com -8.11%

Copyright © Adthena. All rights reserved.

Caplyta.com surged with a 9.50% click share increase, while nurtec.com plummeted by 8.11%. Vraylar.com also rose by 8.72%, contrasting rexulti.com’s 3.82% drop.

Campaign Efficiency

US Pharma & Biotech Neuroscience Share of Impressions

Take a look at the Top 10 competitors in the industry by Share of Impressions over the last month.

See more data
Date vraylar.com nurtec.com caplyta.com cobenfyhcp.com vraylarhcp.com vyepti.com ubrelvy.com fanapt.com caplytahcp.com nurtec-hcp.com
2025/04/01 0% 13.75% 0% 0% 33.14% 0.19% 0% 0% 0% 8.75%
2025/04/02 0% 13.9% 0% 0.15% 30.36% 0.01% 0% 8.21% 0% 6.11%
2025/04/03 0% 11.51% 0% 0% 13.2% 0% 0% 11.46% 0% 18.61%
2025/04/04 0% 10.42% 0% 2.98% 8.09% 1.78% 1.78% 12.47% 0% 5.59%
2025/04/05 18.09% 7.95% 6.61% 0.23% 12.08% 1.04% 1.58% 6.37% 2.21% 3.46%
2025/04/06 7.62% 4.67% 6.99% 6.48% 0% 0.46% 1.85% 11.32% 4.19% 2.02%
2025/04/07 16.84% 5.26% 1.54% 7.96% 0.04% 9.61% 9.79% 9.15% 2.98% 2.23%
2025/04/08 24.73% 6.83% 0% 2.69% 5.04% 0.87% 1.66% 4.36% 0.12% 4.26%
2025/04/09 6.17% 8.25% 2.31% 4.12% 0% 15.91% 13.92% 2.13% 2.26% 10.27%
2025/04/10 3.4% 4.92% 1.25% 5.22% 0% 12.19% 3.95% 3.95% 6.69% 9.99%
2025/04/11 8.22% 13.12% 4.56% 1.47% 4.11% 16.96% 14.67% 1.54% 3.05% 11.6%
2025/04/12 6.99% 8.04% 2.53% 3.49% 7.13% 6.07% 0.97% 8.23% 2.53% 4.53%
2025/04/13 10.84% 13.29% 0% 2.87% 5.39% 12.52% 7.07% 8.98% 0% 9.22%
2025/04/14 14.54% 6.08% 7.09% 6.7% 9.71% 4.21% 0.09% 5.68% 7.02% 2.97%
2025/04/15 31.06% 7.58% 5.67% 2.21% 10.43% 4.87% 0.65% 3.53% 1.93% 5.07%
2025/04/16 0% 8.22% 0.09% 0.27% 20.88% 5.44% 2.56% 4.69% 4.21% 4.56%
2025/04/17 11.09% 3.11% 5.94% 4.63% 3.72% 12.08% 6.95% 4.39% 3.9% 5.07%
2025/04/18 13.07% 5.4% 4.72% 5.99% 0.06% 6.66% 10.15% 2.59% 0.07% 6.8%
2025/04/19 20.43% 4.51% 9.1% 3.83% 4.09% 10.03% 5.08% 5.11% 4.61% 5.76%
2025/04/20 7.38% 7.88% 8.88% 5.34% 0.04% 5.08% 4.35% 5.16% 2.68% 4.58%
2025/04/21 25.28% 6.93% 6.96% 7.45% 3.22% 4.96% 5.12% 4.2% 3.36% 4%
2025/04/22 17.7% 9.51% 4.86% 5.98% 0% 5.06% 10.22% 2.28% 3.07% 10.65%
2025/04/23 0% 4.26% 10.65% 4.9% 0.01% 13.81% 13.71% 0.01% 6.53% 7.22%
2025/04/24 19.98% 19.14% 7.33% 0.58% 0.11% 13.03% 1.69% 0.26% 3.92% 12.38%
2025/04/25 14.43% 11.37% 0.74% 14.03% 0.31% 2.36% 3.93% 9.36% 0.57% 2.58%
2025/04/26 33.71% 7.94% 15.63% 0.52% 0% 3.52% 4.78% 0.01% 12.55% 1.49%
2025/04/27 0% 9.95% 32.26% 0.02% 0.01% 2.23% 0.42% 7.2% 10.76% 1.29%
2025/04/28 10.7% 7.71% 15.37% 0.15% 21.18% 2.85% 2.72% 0.01% 3.85% 1.81%
2025/04/29 35.93% 7.6% 7.91% 0.23% 14.53% 1.26% 2.14% 0% 5.27% 1.24%
2025/04/30 20.26% 10.37% 7.38% 7.04% 6.85% 5.3% 5.16% 3.28% 2.46% 0.54%

Copyright © Adthena. All rights reserved.

In April 2025, Vraylar.com saw fluctuating ad impressions, peaking at 35.93% on the 29th. Nurtec.com maintained moderate visibility, while Caplyta.com surged on the 27th with 32.26%. The month concluded with Vraylar.com leading.

Campaign Efficiency

Google Text Ad Copy Insights & Creative Trends for US Pharma & Biotech Neuroscience

Ever wondered how your rivals’ ads are doing? Here we can see the top-performing ads in the industry over the last month.

See more data
  1. 1
    Suffering From Schizophrenia? - See Treatment Prescription treatment website

    Learn about an FDA-approved treatment that may help adult schizophrenia symptoms. Talk to your healthcare provider to see if this treatment option...

  2. 2
    MAVENCLAD® - (cladribine) tablets 10 mg https://imready.mavenclad.com/patients

    See PI, Safety Information, and Boxed Warning to learn more about MAVENCLAD®.

  3. 3
    FDA-Approved Treatment Option - Types of Migraine Treatment

    Discover if this treatment could help your patients suffering from migraine attacks. Explore resources for an Rx to help your patients treat migraine attacks.

  4. 4
    VRAYLAR® (cariprazine) - Medication Information https://www.vraylar.com/

    See VRAYLAR® (cariprazine) Full Prescribing Information, Including Boxed Warnings. Start the Conversation With Your Healthcare Provider About...

  5. 5
    VRAYLAR® (cariprazine) - Healthcare Professional Site https://www.vraylarhcp.com

    Learn About VRAYLAR®. See Full Prescribing Information, Including Boxed Warnings. See VRAYLAR® Dosing and Administration Information Here. Visit the Site to Learn More.

Copyright © Adthena. All rights reserved.

In the competitive landscape of pharmaceuticals, top-performing Google PPC ads reveal a focus on FDA-approved treatments. Fanapt.com targets schizophrenia sufferers, emphasizing healthcare provider consultations. Mavenclad.com highlights safety information for cladribine tablets. Nurtec-hcp.com offers migraine treatment resources, while Vraylar.com and Vraylarhcp.com provide comprehensive medication information for healthcare professionals.

Frequently Asked Questions

Customer Success Stories

the7stars Case study: PPC campaign Optimization

the7stars case study: Achieving Google Ads PPC campaign optimization​ with Adthena

Leveraging Adthena's comprehensive insights, the7stars and their lottery client optimized their PPC campaigns and organic strategies, resulting in substantial cost savings and improved campaign performance. Read case study
Sage Case study: Brand protection strategy

Sage case study: 75% decrease in CPCs with Adthena

Sage, a leading UK software provider, used Adthena’s brand protection strategy to curb rising CPC costs. By identifying brand infringements and optimizing spend, they effectively strengthened their brand protection strategy and increased ROI.Read case study

Vodafone case study: Driving click share and sales with strategic insights from Adthena

Vodafone used Adthena data to optimize results from the launch of the Samsung S22 product. Combining Adthena’s Strategic Insights with Google Smart Bidding, Vodafone was able to maintain a flexible strategy that leveraged both manual and automated bidding. Leveraging Adthena’s Search Term Opportunities report also allowed Vodafone to implement 27 keyword terms across their business line, driving an increase in revenue at a positive ROAS.Read case study

Get the full picture

See this data specific to your brand performance

The data on this page is just a sample of the billions of data points we hold at Adthena. The insights generated by Ask Arlo, leverage real-time GenAI to answer questions about your search data.

Our search consultants can introduce you to Whole Market View data that is specific to your organization, based on the size of the relevant search term and competitor universe, and the locations that you need monitoring.